mln9708
Triple-Negative Breast Cancer
Arbeitsgemeinschaft medikamentoese TumortherapiePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
6 Active assets in the Triple-Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Famitinib Fudan University | Phase 3 | BB |
Romidepsin Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 2 | B |
Odetiglucan HiberCell, Inc. | Phase 2 | B |
Endotag-1 SynCore Biotechnology Co., Ltd. | Phase 3 | B |
Talzenna Melinda Telli | Phase 2 | B |
View all 17 →
Same molecule, other indications
mln9708 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →